Jocelyn Keider is a litigator with a focus on securities litigation and enforcement matters. She represents public companies, including biopharmaceutical companies, technology companies, and financial institutions, as well as their officers and directors in complex class action and derivative cases in federal and state court. Ms. Keider also maintains an active pro bono practice.

Ms. Keider has experience handling fast-moving and complex litigation cases on behalf of her clients: she has drafted dozens of briefs, managed complex discovery disputes, prepared both expert and lay witnesses for testimony, taken depositions, and appeared in court on behalf of clients in a number of forums, including federal district court, state court, and immigration court.  Ms. Keider also assists clients in responding to SEC subpoenas and shareholder books and records demands.

While pursuing her legal education, Ms. Keider was a student attorney with the Harvard Legal Aid Bureau. In this capacity she served as lead counsel on 11 cases, argued numerous motions and handled a four-day bench trial in probate court, during which she conducted both direct and cross examinations. As a law student, Ms. Keider's commitment to pro bono work was recognized by the Massachusetts Supreme Judicial Court's Pro Bono Honor Roll.


  • Ms. Keider has been an integral member of WilmerHale teams that have achieved the following positive outcomes on behalf of clients:

    • In re Karyopharm Sec. Litig., 552 F. Supp. 3d 77 (D. Mass. 2021),  aff’d sub nom. Thant v. Karyopharm Therapeutics Inc., 43 F.4th 214 (1st Cir. 2022): District Court dismissed securities fraud class action against biopharmaceutical company on a variety of grounds, including lack of falsity and scienter, in matter arising out of claims that company failed to disclose serious adverse events and other issues related to its Phase III clinical trials.  First Circuit affirmed.
    • Goucher et. al v. Iterum Therapeutics, PLC, et. al., 2022 WL 17976164 (D. Ill. Dec. 29, 2022): Court dismissed complaint arising out of claims that company failed adequately to disclose supposed flaws in clinical trial design, weaknesses in clinical data, and communications with FDA, finding that information was publicly available, defendants had made adequate risk disclosures, and that defendants’ statements were not misleading. Plaintiffs did not attempt to replead or appeal.
    • In re AnaptysBio, Inc., 2021 WL 4267413, at *1 (S.D. Cal. Sept. 20, 2021): District Court dismissed securities fraud action arising out of claims that biotechnology company failed to disclose details of clinical trial design and supposed weaknesses in clinical data, finding that plaintiffs failed to allege a materially misleading statement and failed to allege scienter.
    • Huang v. Assertio, 443 F. Supp. 3d 1031 (N.D. Cal. 2020): District Court dismissed securities fraud class action against an FDA-regulated company based on allegations that the company promoted its product off-label and failed to disclose regulatory risks associated with its sales practices. Ms. Keider successfully presented oral argument for dismissal of amended complaint. The matter was then favorably resolved on appeal.
    • Achieved reunification of mother and child separated at the US-Mexico border. Filed complaint and motion for preliminary injunction in federal court, steps which eventually led to the successful reunification of the family in July 2018.
    • Represented international auto parts manufacturer in US civil antitrust litigation following a finding of cartel activity in Europe, securing favorable settlement of all class actions.


Insights & News


  • Education

    • JD, Harvard Law School, 2015

      Vice President of Membership, Harvard Legal Aid Bureau

    • BA, English, University of California, Los Angeles, 2011

      summa cum laude

  • Admissions

    • Massachusetts



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.